Methaver 100

Methandienone

Methaver 100

Methaver 100 is a pharmaceutical-grade oil-based injectable formulation of Methandienone (also designated Methandrostenolone) at 100 milligrams per millilitre, presented in a 10 mL multiple dose vial. Methandienone is a synthetic derivative of testosterone carrying a 1,2-double bond in the A-ring and a 17-alpha methyl group, a structural configuration that produces a markedly elevated anabolic-to-androgenic ratio relative to the parent hormone.

Structural Profile

Methandienone is formally described as 17-beta-hydroxy-17-alpha-methylandrosta-1,4-dien-3-one, with the molecular formula C20H28O2 and a molar mass of 300.44 g/mol. Two modifications distinguish it from testosterone: the introduction of a double bond between carbons 1 and 2, which substantially reduces affinity for the aromatase enzyme and increases anabolic potency, and 17-alpha alkylation, which confers resistance to enzymatic degradation. The compound is registered under CAS number 72-63-9.

Formulation

Unlike conventional methandienone presentations, which are compressed into tablets for oral administration, Methaver 100 suspends the active compound in a sterile pharmaceutical carrier oil for intramuscular injection. The oil vehicle forms an intramuscular depot from which the compound is released gradually into systemic circulation. Because the compound is introduced directly into the muscle tissue rather than the gastrointestinal tract, it bypasses hepatic first-pass metabolism entirely. This route of administration is the principal pharmacological distinction between the injectable and oral presentations of the same molecule.

Pharmacokinetic Profile

The plasma elimination half-life of methandienone is approximately 4 to 6 hours, a property of the molecule itself and independent of the route of administration. The oil depot created by intramuscular injection, however, extends the absorption phase and produces a flatter serum concentration curve than that observed following oral dosing, where peak plasma levels are reached within 1 to 3 hours and decline rapidly thereafter. Detection windows for methandienone metabolites in urine typically extend to approximately 5 to 6 weeks depending on assay sensitivity and individual metabolic clearance rate.

Mechanism of Action

Methandienone binds to the cytoplasmic androgen receptor, and the resulting hormone-receptor complex translocates to the cell nucleus where it interacts with hormone response elements on target DNA. This interaction upregulates transcription of genes governing structural protein synthesis in skeletal muscle tissue. The compound additionally increases nitrogen retention within muscle cells and enhances glycogenolysis. The 1,2-double bond markedly reduces the rate of conversion to estradiol by aromatase relative to testosterone, although methandienone retains a degree of aromatisation to methylestradiol.

Manufacturing and Sterility

Each batch of Methaver 100 is compounded under GMP conditions and subjected to the full pharmaceutical release testing protocol prior to distribution, including HPLC identity confirmation and purity analysis, concentration verification against label claim, sterility testing per USP <71>, bacterial endotoxin quantification by LAL assay, and particulate matter inspection per USP <788>.

Quality Assurance

Every batch of Methaver 100 produced by Biomedica undergoes the complete pharmaceutical release testing protocol before distribution. This includes HPLC compound identity confirmation and purity analysis (specification: ≥98%), concentration verification (specification: ±5% of label claim), sterility testing per USP <71>, bacterial endotoxin quantification by LAL assay (specification: <0.25 EU/mL), and particulate matter inspection per USP <788>. A Certificate of Analysis is issued for every production lot.

Authentication

Each unit of Methaver 100 carries a unique authentication code on its outer packaging. This code can be verified instantly on our Authentication page to confirm the product is genuine Biomedica stock.